NeoPhore Ltd.

https://www.neophore.com

NeoPhore, based in Cambridge, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Cancer neoantigens are known to stimulate the immune system and potentially be a weak spot in a tumour cell’s defence mechanisms. The Company’s approach targets genetic mechanisms that both clinical and lab studies suggest will promote neoantigen creation and diversity across numerous cancers. Using these insights, the Company aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of PhoreMost Ltd and is backed by Sixth Element Capital LLP, a UK based fund manager established to manage investments for the £70 million CRT Pioneer Fund. *

	Start	2017-11-15 established (s-off)
	Predecessor	PhoreMost Ltd.
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	small-molecule cancer drug
	Person	Baker, Matthew (Matt) (NeoPhore 202003– CEO joined 5/19 before Denceptor Therapeutics + Abzena + Antitope + Biovation)
	Person 2	James, Robert (SIxth Element Capital 2010– Managing Partner + Co-Founder before DFJ Esprit + Prelude Ventures + CRT)

	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	Babraham Research Campus Babraham Research Campus (Bldg. B580, Room 2011)
	City	CB22 3AT Cambridge, Cambridgeshire
	Tel	+44-1223-804250
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: NeoPhore Ltd.. (3/20/19). "Press Release: NeoPhore Appoints Dr John Haurum as Non-Executive Director. Former F-star CEO Joins the Board of Directors".

		Record changed: 2023-07-10